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Abstract 
 
Objective: To develop a study design for rare disease clinical trials (RDTs) that can 
efficiently evaluate treatments, promotes access to new treatments during treatment 
development, and optimizes healthcare resource utilization for future treatment allocation, 
development, and prioritization.   
Study design and setting: Comprehensive literature review and focus group discussion were 
conducted. We incorporated aspects other than treatment effect evaluation into the study 
design to address the multifaceted challenges facing RDTs.  
Results: The four key considerations for RDTs are: 1) patients’ opportunity to access the 
new treatment; 2) assessment of outcomes where clinically validated outcomes may be 
lacking; 3) patient heterogeneity; and 4) duration of the study and number of patients 
required. Our proposed study design has two stages. Stage 1 distinguishes patients who 
respond to the treatment from those who do not respond to the treatment after assigning 
them all to the experimental treatment. Stage 2 evaluates the treatment effect 
comparatively among patients responded in Stage 1.  
Conclusion: In addition to treatment effect evaluation, RDTs can potentially great benefit 
rare disease patients and clinical practice by increasing opportunities to access 
experimental treatments and by providing relevant information that can be used for 
tailoring treatments to certain subgroups, aiding future research in treatment development, 
and improving healthcare resource utilization.  
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What is new? 
This proposed study design has two stages: in Stage 1, all patients receive the 
experimental treatment; and in Stage 2, treatment effect is evaluated on patients whose 
outcome(s) improved in Stage 1 using either a cross-over design, series of n-of-1 trials, 
or a response-adaptive design, depending on the characteristics of the disease, 
treatments, and outcome(s) of interest. The design of both stages allows greater 
opportunity for patients to access the experimental treatment compared to a standard 
parallel design, which is often a critical consideration for patients. 
This study design includes two salient features: (1) Responses to the experimental 
treatment are assessed at stage 1 with respect to patient characteristics to allow for 
better understanding of the experimental treatment responses, which is often 
inadequate for rare diseases. This also allows more tailored administration of treatment 
to future patients; and 2) there are three study design options for treatment effect 
evaluation in Stage 2, all of which allow greater opportunity for patients to access the 
experimental treatment. 
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1. Introduction 
  A disease is defined as rare if it affects less than 1 in 2,000 people in the 
population [1]. With over 6,000 diseases falling into this characterization, approximately 
6-8% of people worldwide are afflicted with a rare disease [2-3]. Although rare diseases 
present a substantial burden to patients and healthcare systems, there are often little or no 
effective treatments available and the diseases themselves are poorly understood [4-6].  
  There are many challenges with using the standard randomized controlled trial 
(RCT) framework to evaluate treatment effect for rare diseases. These include small 
patient numbers, lack of validated clinical endpoints, lack of knowledge of the disease, 
and heterogeneity in patient characteristics, all due to the rarity of diseases [7,8]. High 
research and development costs for a small patient population present an additional 
challenge faced for orphan drug development, making them both scarce and expensive 
[7,9]. In turn, this limits the accessibility and availability of new treatments to 
patients[10,11], a critical issue which needs to be considered for rare disease patients and 
the trials of orphan drugs for them. A patient-centered trial design that promotes access to 
new treatments and optimizes healthcare resource utilization for future treatment 
allocation, development, and prioritization is urgently needed for rare diseases.  
   We propose a study design for rare disease trials (RDTs) that evaluates treatment 
effect comparatively under the standard trial requirements (i.e., randomization, blinding, 
allocation concealment), while promoting access to new experimental treatments for rare 
disease patients, and the understanding of the disease itself. Under this design, all 
enrolled patients have access to the experimental treatment; patient characteristics that 
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are found to be associated with treatment response can inform tailoring of treatments 
based on patient characteristics in clinical practice.  
2. Methods  
The development of our study design followed the research plan outlined as follows:  
(1) A comprehensive review of relevant literature to understand the issues surrounding 
the evaluation of rare disease treatments in clinical trials and to identify study designs 
that have already been applied and/or proposed.  
(2) Discussions of key considerations for a study design among patients, researchers, 
clinicians, policy makers, and other stakeholders in order to address issues that rare 
disease clinical trials have in evaluating treatment effect.  
(3) The development of a new study design for rare disease clinical trials, including key 
considerations that were developed as a result of the undertakings in 1) and 2).   
 We systematically searched in PubMed for English-language publications using 
multiple combinations of search terms (Table 1) in PubMed and included relevant 
literature published up to 31 May 2016.  Based on the search results, JY scanned the titles 
and abstracts of 3,292 papers using three broad inclusion/exclusion criteria: 1) discussion 
of challenges with RDTs, 2) review of previously proposed RDT study designs or 3) 
application of RDT study designs. JY deemed 216 articles to meet these preliminary 
criteria and SM independently verified that all 216 articles were relevant given the study 
objective.
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a. Reversible outcomes refer to outcomes that can be deemed to be reversed back after a washout period 
to their baseline state. Non-reversible outcome are outcomes that cannot be reversed back to the 
baseline state of disease through washout. 
  A more comprehensive review of all 216 papers was carried out by JY and SM 
and they mutually agreed to include 68 papers for a more comprehensive review (15 
focused on challenges with RDTs, 17 reviewed previously proposed RDT study designs 
and 36 discussed applications of RDT study designs). 
 A list of key considerations was created in a small-group consultation setting with 
experts and annual meetings for the Promoting Rare Disease Innovation through 
Sustainable Mechanisms (PRISM) workgroup in 2013 and 2014. Together with the 
literature identified above, a list of important considerations for RDT’s was developed.  
 Following additional discussions with two experts (Dr. Robin Casey, a physician 
involved in providing care for rare disease patients, and Dr. Robyn Lim, a senior 
scientific advisor at the Office of Legislative and Regulatory Modernization at Health 
Canada), a list of four key considerations was finalized. With the inclusion of these key 
considerations, we developed a new study design for RDTs. 
3. Results  
  We first list the four key considerations. Next we describe our study design for 
RDT’s where the target outcome of the disease is reversiblea. In section 3.3, possible 
modifications that can be made to the proposed study design for non-reversible outcomes 
are described. Details on how this study design satisfies the four key considerations are 
given in the discussion section.   
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3.1 List of considerations 
   The four key considerations for RDTs which were used to develop our study 
design are: 1) patients’ opportunity to access the new treatment; 2) assessment of 
outcomes where clinically validated outcomes may be lacking; 3) patient heterogeneity; 
and 4) duration of the study and number of patients required.  
  In addition, we encourage investigators to include patients in the clinical trial 
committee prior to the onset of the trial. Several studies has shown that the inclusion of 
patients as informed decision makers, rather than just study subjects, can identify blind-
spots that may have been missed by investigators [12, 13]. For example, the Outcome 
Measures in Rheumatology (OMERACT) group discovered outcomes which were 
important to patients with rheumatoid arthritis but had previously been missed by 
investigators, such as fatigue, foot pain, and sleep disturbances [14]. Thus, consulting or 
including patient representatives when planning of clinical trial can potentially elucidate 
new outcomes of interest and also identify how they may be measured during the trial. 
   
3.2 Overview of the Proposed Study Design 
  In order to satisfy all four criteria, we propose a study design that has two stages. 
Stage 1 distinguishes patients who respond to the treatment (“responders”) from those 
who do not respond to the treatment (“non-responders”) after assigning them all to the 
experimental treatment. Stage 2 evaluates the treatment effect comparatively among 
those patients characterized as responders in Stage 1 (Figure 1).    
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3.2.1 Proposed Stage 1  
   Upon enrolment in Stage 1, detailed baseline characteristics of all enrolled study 
patients, which include demographic information (e.g., age and sex), specific 
clinical/biological information such as characterizations of the disease, symptoms, known 
biomarkers for the disease, and other physiological measurements, are collected. All 
enrolled patients are then given access to the experimental treatment. Patients’ symptoms 
and clinical characteristics of the disease are monitored throughout Stage 1. 
  At the end of Stage 1, patients are characterized as either responders or non-
responders. Responders are patients who respond positively to the treatment from patient 
self-reports and/or clinical evaluation that meet pre-specified criteria. If few or no 
patients are characterized as responsive at the end of Stage 1, the trial will be stopped 
with the conclusion that the treatment is overall ineffective. If responders exceed a pre-
specified percentage, responders will proceed to Stage 2 while non-responders will be 
withdrawn from the trial. In the study protocol, investigators should clearly specify the 
criteria of responding to treatment and the minimum proportion of respondents that is 
needed to be observed at the end of Stage 1 to justify the proceeding to Stage 2.  
 Information about patient characteristics collected at baseline will be analyzed to 
assess the association between baseline patient characteristics and treatment response in 
order to gain understanding of the responses to the experimental treatment (e.g. side 
effects, quality of life improvement). This analysis can be done using standard statistical 
methods of binary outcomes (response vs. non response) such as logistic regression. 
Using the results from this analysis, patient subgroups can be created based on specific 
sets of characteristics that predict patients who are likely to benefit from and/or be 
10 
 
 
harmed by the experimental treatment. This is useful information that can aid future 
treatment allocation, development, and prioritization since treatment accessibility and 
availability in rare disease populations are usually limited.  
3.2.2 Proposed Stage 2 Framework 
  Following a washout period, patients who were characterized as responders in 
Stage 1 proceed to Stage 2 to evaluate the efficacy of the experimental treatment using a 
randomized controlled trial design. Depending on the characteristic of the outcomes of 
the rare disease under study, the investigator will choose an appropriate study design for 
evaluating the treatment effect in Stage 2.   
 Out of at least 14 different study designs [15-17], we shortlist three for use in 
Stage 2: cross-over design; series of n-of-1 trials design; and response-adaptive design 
(Table 2). These study designs were selected because they include randomization, 
allocation concealment, blinding of treatment allocation, and also allow for interim 
analysis. All three study designs further provide enhanced opportunities for enrolled 
patients to access the experimental treatment.  
  The use of interim analysis can potentially make treatment effect evaluation at 
Stage 2 more efficient. During Stage 2 interim analysis, if patients’ outcomes have 
already been found to have substantially improved, then fewer patients and shorter study 
period than anticipated may be required for Stage 2.  
  For specific RDT scenarios, one of these study designs may be more suitable than 
others.  A summary of these three designs’ features are given here: 
1) Cross-over design 
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 Definition: patients are randomly assigned to receive two or more treatments 
sequentially with wash-out periods between consecutive treatments and each 
patient acts as his/her own control [18]. 
 Assumptions: there is no treatment-period interaction and negligible carryover 
effect. Under these assumptions, statistically-valid comparison of two or more 
treatments is possible. [18]. 
 Advantages: since the comparison of treatment effect is within the same 
patient, this study design can more precisely estimate treatment effect than 
adaptive design where patient characteristics are heterogeneous [16,19-24].  
 Limitations: 1) longer study duration is required than adaptive design because 
each patient receives more than one treatment; 2) sufficient washout period is 
required between each treatment received; and 3) consequences of dropouts 
are greater than adaptive design because more information is lost per dropout 
[18-24]. 
 Analysis: generalized linear model can be used in which the outcome can be 
binary or continuous. The effect of treatments, carry over, and periods are 
captured appropriately and evaluated in the model [25].  
2) Series of n-of-1 trials design 
 Definition: two or more treatments are consecutively and repeatedly given in a 
random order to each patient who contributes information to one n-of-1 trial. 
A series of n-of-1 trials are analyzed jointly for treatment effect evaluation 
[18, 20, 26]. 
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 Assumptions: there is no treatment-period interaction and no carry over effect 
[18, 20, 26], under which comparing multiple treatments is statistically valid. 
 Advantages: since this design is capable of assessing the effect of the 
treatment on each patient, it can estimate treatment effect more precisely when 
the disease is extremely rare and when patient characteristics are highly 
heterogeneous [18 20, 26]. 
 Limitations: 1) longer study duration is required due to a greater number of 
treatments received and/or more repetition of same treatments received than 
cross-over design and adaptive design; 2) similar to cross-over design, 
sufficient washout period is required between treatments received; and 3) the 
consequences of dropouts are greater than adaptive design because more 
information is lost per dropout. 
 Analysis: meta-analysis can be performed for this study design by aggregating 
the data of each n-of-1 trial to obtain the average treatment effect for the 
population and individual patient, as well as estimates of between-patient 
variation [27, 28]. 
3) Response-adaptive study design 
 Definition: a study design that allows modification of randomization schemes 
during the trial based on interim trial results. This is done by varying the 
probabilities of treatment assignment to increase the likelihood of patients 
being assigned to the superior treatment and minimizing the number of 
patients exposed to the inferior treatment [14, 18, 20, 29-34]. 
13 
 
 
 Advantages: 1) carry over effect is not an issue because patients receive only 
one treatment; 2) the study duration is generally shorter than cross over trials 
and series of n-of-1 trials since patients only receive one treatment; 3) 
response-adaptive design is a parallel group design if no adaptation is made 
during the trial; and 4) the outcome response of previous patients can guide 
trials to assign the better treatment with high probabilities to newly recruited 
patients. 
 Limitations: 1) not suitable for heterogeneous populations; and 2) complex 
statistical analysis is usually required under frequentist statistical inference 
[14, 18, 20, 29-34]. 
 Analysis: maximum likelihood estimation with consideration of correlation 
and permutation test are suggested as the analysis method for this study design 
[30, 33].   
   Stage 2 analysis, as in Stage 1, includes the perspective of enrolled patients for 
treatment effect evaluation since patient feedback is important information in determining 
the experimental treatment’s effectiveness: it describes aspects of patients’ experiences 
with the treatment that can be only obtainable from its actual users (e.g. pain, dizziness). 
3.3 Potential modification for non-reversible outcomes  
 When the disease outcome is non-reversible, modifications to the study design are 
necessary to adequately evaluate treatment effect. For example, patients may show 
improvements in Stage 1 that are non-reversible; the continued administration of the 
experimental treatment in Stage 2, however, may do little to change their outcome from 
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the "new" Stage 2 baseline. This can make it much harder to measure the effect of 
experimental treatment versus placebo or other treatment in Stage 2.  
  Thus, for non-reversible outcomes, Stage 2 in our proposed study design should 
be modified by recruiting new patients directly into Stage 2 instead of using Stage 1 
patients. Patient characteristics collected in Stage 1 will be used to examine what 
subgroups of patients did not respond or had an adverse response to the treatment. New 
recruitment will have the same inclusion criteria as Stage 1 but will exclude patients who 
possess characteristics that were found to be associated with treatment non-response in 
Stage 1. By excluding patients who are unlikely to benefit from the experimental 
treatment, Stage 2 will focus the treatment effect evaluation on patients who are more 
likely to respond.  
4. Discussion 
  It is estimated that up to 8% of the world population has a rare medical condition 
[2]. Since rare disease treatments often cost much more than what many patients can 
afford, funding for the treatment access of a small population could significantly impact 
the budget of healthcare systems [2]. Furthermore, since there is limited information 
related to the epidemiology of many rare diseases and rare disease treatment effects, 
treatment in clinical practice might often be done with limited evidence , which may 
result in poor utilization of healthcare resources [1]. Thus, a study design that can aid 
prioritization of resource utilization in treatment development, treatment allocation in 
clinical practice and provides more treatment access opportunities to patients, as well as 
evaluates the treatment’s effects, would make effective treatments more available for rare 
disease patients and would better utilize the resources of developing clinical trials and 
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public funding subsidization. In sections 4.1-4.4, we discuss why each key consideration 
is important in these regards and then describe how each stage of our study design 
satisfies the consideration. A summary is given in Table 3. 
4.1 Consideration 1: Patient Opportunity to Receive the Experimental Treatment 
   For many rare diseases, there may be a lack of industry incentive to develop 
treatments for several reasons: 1) there may be insufficient scientific interests; 2) a small 
number of patients to treat is perceived as relatively low return on investment which may 
impede treatment development; and 3) the poorly understood etiology means that 
treatment development is less certain due to factors such as a lack of pharmacological 
targets for intervention. As an ethical consideration, it would greatly aid rare disease 
patients if RDTs made treatment access a priority given the scarcity of treatment access 
opportunities in the rare disease community. 
  In order to enhance treatment access for patients in the trial, Stage 1 of our 
proposed study design is an “enrichment” stage where all patients enrolled in the trial 
receive the experimental treatment. In addition, Stage 2 for treatment effect evaluation 
employs study designs that give patients more opportunity to access the experimental 
treatment compared to a parallel group design. Specifically, n-of-1 and cross-over study 
designs ensure that all patients receive the experimental treatment during the treatment 
effect evaluation in Stage 2. For response-adaptive designs, the probability of receiving a 
superior treatment increases as the trial progresses, so patients have a greater chance of 
being selected into the superior treatment arm.  
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4.2 Consideration 2: Assessment of outcomes where clinically validated outcomes 
may be lacking 
The effectiveness of a treatment in clinical trials is usually based on well-
characterized clinical outcomes [5]. If validated clinical outcomes are lacking, then it is 
challenging to justify the treatments effect on patients’ health conditions. Therefore, it 
would aid treatment effect evaluation if RDTs can evaluate treatment effects where no 
clinically validated endpoints for a disease are available. 
  In section 3.1, we suggest including patients as shared decision makers, prior to 
the start of the trial. Our study design itself also takes outcome measurement into 
consideration in both stages. In Stage 1, we measure a range of modifiable patient 
characteristics before and after the treatment is administered and monitor the changes. 
This information can then be incorporated in Stage 2 to define endpoints. In both Stages 1 
and 2, patient-feedback is considered in the evaluation of treatment response. The 
measurements of modifiable patient characteristics and patient-feedback provide 
information about outcomes/endpoints relevant to evaluate treatment effect: they may 
also provide information about how the administration of the experimental treatment can 
be developed to be more patient-friendly [4].  
4.3 Consideration 3: Patient Heterogeneity 
  Many rare diseases populations are known to be heterogeneous [2]. Patients with 
certain characteristics might respond to the experimental treatment whereas others might 
not. Since rare disease treatments are often expensive and scarce, the association between 
patient characteristics and treatment response is an important consideration for treatment 
development and prioritizing treatments for patients who are likely to respond in the 
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clinical practice. This could also provide future direction for treatment development by 
potentially providing information regarding plausible biological mechanisms of 
treatments being more effective for certain patients than others.  
  To account for patient heterogeneity in Stage 1, we screen for responders and 
explore the patient characteristics associated with treatment response. This information is 
then used to create patient subgroups based on patient characteristics. For example, if a 
common biological marker exists among all responders but not among non-responders, 
this can inform new areas for pharmaceutical intervention and can also prioritize 
treatment allocation in the clinical setting. In Stage 2, only patients who responded to the 
treatment in Stage 1 are assessed, and hence the evaluated treatment effect is more 
specific to certain groups of the patient population that may benefit from the treatment.  
4.4 Consideration 4: Duration of the study and recruitment of a sufficient number of 
patients 
  An efficient study design can get an effective intervention to rare disease patients 
more quickly by avoiding an unnecessarily long study period. For RDTs, a long study 
period is often required to recruit a sufficient number of patients into the study: 
finding/identifying the specific rare disease patients who may be geographically 
dispersed takes time. For these reasons, investigators should consider how the trial can be 
made more efficient without sacrificing patient safety and the integrity of the trial.  
  In our study design, investigators are asked to specify, in the study protocol, the 
minimum proportion of patients responding to treatment in Stage 1 to justify proceeding 
to Stage 2. If this proportion of responding is not met in Stage 1, the trial is stopped 
without proceeding to Stage 2. For Stage 2, interim analysis is used; again, if sufficient 
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response is not seen, as specified in the study protocol, the trial is stopped. This improves 
efficiency and also helps with resource utilization by stopping the trial, should the 
treatment be found ineffective at an earlier point.  
  Additionally, in section 3.5, we describe a modification that can be made for non-
reversible outcome. However, this modification can also be used to enhance efficiency. If 
a clear pattern of patient characteristics are found to be associated with treatment 
response in Stage 1, the study design can be modified by having newly recruited patients 
enrol directly into Stage 2. One limitation of this modification is that if a response-
adaptive design is used in Stage 2, some patients may not get the opportunity to access 
the experimental treatment. The impact of such a loss of opportunity should be 
considered prior to making such a study design modification. 
4.5 Comparison with randomized withdrawal design  
  Our study design shares some similarities with a previously proposed RDT study 
design, the randomized withdrawal design [34-42]. Specifically, both our proposed study 
design and the randomized withdrawal design have 2 phases/stages; there is an initial 
enrichment stage where all recruited patients receive the experimental treatment and only 
patients who respond to the treatment continue to the second stage for treatment effect 
evaluation.  
  The salient features of our design are: 1) the association of patient characteristics 
and responsiveness to the experimental treatment are analyzed at the end of Stage 1; and 
2) there are three study design options to evaluate treatment effect in Stage 2. Regarding 
feature 1), we gain knowledge on patient subgroups for which the treatment is effective, 
which has important implications for treatment development, allocation, and 
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prioritization. On the other hand, the randomized withdrawal design is often motivated to 
“enrich” the patient population and increase study power in the second stage’s efficacy 
evaluation [37]. With feature 2), more study design options in Stage 2 makes it possible 
to evaluate treatment effect for a greater number of rare diseases with the proposed 
designs in our framework, such as cross-over design, series of n-of-1 trials, compare to 
randomized withdrawal design in which only the parallel group design is used in Stage 2. 
In addition, our design considers a greater scope of specific RDT issues that patients, 
healthcare providers, funders and treatment developers face as described above. 
4.6 Limitations 
  This proposed RDT framework has some potential limitations which should be 
considered. In general, investigations of the association between patient characteristics 
and treatment response in a clinical trial are recommended to be exploratory: the 
association may be specific to some aspects of the trial (e.g., season). The results on the 
association from Stage 1 should, therefore, cautiously be generalized to the target 
population. Our suggestion to alleviate this limitation is to ensure sufficient sample size 
for identifying the associations in Stage 1 as well as soliciting from patients and care 
providers possible specific aspects of the trials that may potentially bias the trial results.  
  It is also possible that the treatment is found to be effective following Stage 2, but 
there is ambiguity about how the characteristics of responders and non-responders differ. 
In such a scenario, the trial has a limited capacity to prioritize treatment based on patient 
characteristics. However, the information about treatment effects is still valuable for 
stakeholders in determining the proportion of the target population that is expected to 
respond to the treatment. Given that rare disease treatments often are very expensive, 
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information on the percentage responding and average effect size for responders will help 
with resource utilization. 
  Since the development of this study design did not consider regulatory aspects, 
our study design might be modified after the inclusion of regulatory aspects.  
5. Conclusion 
  In addition to treatment effect evaluation, RDTs can potentially be of great benefit 
to rare disease patients and clinical practice by increasing opportunities to access 
experimental treatments and by providing relevant information that can be used for 
tailoring treatments to certain subgroups, aiding future research in treatment 
development, and improving healthcare resource utilization. Future work in applying our 
proposed design to rare disease clinical trials is needed in order to evaluate its robustness 
in practice. Although this design has some limitations and may not be suitable for all rare 
disease scenarios, it may serve as a basis for the future development of RDT study 
designs that aim to better fulfill the needs of the rare disease community.   
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Table 1. Search terms for the identification of articles on rare disease clinical trial 
topics 
 Rare disease 
 Randomized withdrawal  Crossover 
 Research Design 
 Adaptive design  Series N-of-1 
 Epidemiologic Methods 
 Response adaptive 
design 
 Small Clinical Trial 
 Clinical trials 
 Sequential design  Orphan Drug 
 Ranking and Selection 
 Enrichment design  Orphan 
 N-of-1 
 Clinical Trials as Topics  Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
Treatment B  
Treatment A 
Washout 
Washout Treatment A 
Treatment B 
 
 
 
Table 2. Study design options for Stage 2 treatment effect evaluation 
 
Definition: Advantages: Limitations: 
Randomly assign sequences of 
two treatments to patient 
groups 
 Comparison of two treatments 
 No treatment-period interaction 
 No carry over effect 
 Heterogeneous populations 
 Longer study duration 
 Sufficient washout period 
needed 
 Dropouts have greater 
influence 
 
Definition Advantages: Limitations: 
Randomly assign sequences of 
multiple treatments to only one 
patient in a trial for a series of 
trials 
 Comparison of two or more  
treatments 
 No treatment-period interaction 
 No carry over effect 
 Heterogenous populations 
 Extremely rare disease 
 Longer study duration 
 Sufficient washout period 
needed 
 Dropouts have greater 
influence 
   
Definition: Advantages: Limitations: 
Each treatment's chance of 
being assigned to patients is 
adapted based on accumulated 
patients’ responses to 
treatments  
 Evidence of one superior 
treatment 
 Shorter study duration 
preferred 
 Not suitable for 
heterogeneous populations 
 Complex analysis 
 
Note: “R” represents randomization. Treatment A and B refer to an experimental treatment and a standard 
treatment, respectively. For response-adaptive design, each patient receives Treatment A or B; the probability of 
receiving a specific treatment depends on the number of balls for that treatment in ths “ball-in-urn” design. The 
number of balls in the urn is for illustration due to limited space. The required number of balls varies upon studies. 
A) Cross-Over Design 
R 
B) Series of N-of-1 Trials 
TreatmentA Washout
t 
TreatmentB 
BB 
TreatmentA 
AA 
Washout
tttt 
Washout 
TreatmentB 
B 
TreatmentB 
B 
TreatmentB 
BA 
Washout 
Washout 
Washout 
TreatmentA 
AAAAA 
TreatmentA 
B 
TreatmentB 
B 
C) Response Adaptive Design 
 R 
Treatment A 
Treatment B 
Randomized to  
Treatment A  
 
 Outcome Improves 
 R 
Randomized to  
Treatment B – 
No outcome 
improvement 
 
 
 R 
Randomized to  
Treatment A – 
Outcome 
improves 
 
 
R 
Next patient has 
a 3:1 chance of 
being assigned 
to Treatment A 
vs. Treatment B 
R 
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Table 3. Summary of how the Proposed Design (Stage 1 and 2) Satisfy the Four Key 
Considerations 
Key Considerations Rationale Stage 1 Stage 2 
1. Patient 
opportunity to 
access the new 
treatment 
Due to a lack of 
accessible and effective 
treatments, treatment 
access is a high priority 
for rare disease patients  
All patients receive the 
experimental 
treatment  
Study designs give 
more opportunity to 
patients to receive 
treatment or the 
superior treatment 
than  parallel group 
design does 
2. Assessment of 
outcomes where 
clinically validated 
outcomes may be 
lacking 
The trial should evaluate 
treatment effect on all 
rare disease patients 
even without validated 
clinical endpoints so as 
to benefit clinical 
practice 
Patient-feedback on 
treatment effect 
Patient feedback on 
treatment effect 
3. Patient 
heterogeneity 
Treatments should be 
prioritized to those 
patients most likely to 
benefit from them  
- Patients are 
characterized into 
responders and non-
responders 
- Measurement of 
patient characteristics 
and association with 
treatment response 
- Only patients who 
responded to the 
treatment in Stage 1 
are assessed 
- N-of-1 and cross-
over study designs 
in Stage 2 use 
patients as their 
own controls 
 4. Duration of the 
study and number 
of patients required 
An efficient study design 
will get an effective 
intervention to patients 
sooner and will aid 
resource utilization 
If sufficient Stage 1 
improvement is not 
seen, the trial is 
terminated  
- Interim analysis is 
performed to justify 
continuing the trial 
- Only responders 
from Stage 1 
patients are 
evaluated for 
treatment effects 
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Figure 1. Overview of the proposed framework 
During Stage 1, all patients receive the experimental treatment and are identified as 
“responders” or “non-responders” based on their outcome improvement. Following a 
washout period, responders proceed to Stage 2 for comparative evaluation of treatment 
effects among them. Analysis has two goals: 1) estimation of the average treatment 
effect on responsive patients; and 2) comparison of the characteristics of responsive 
and non-responsive patients.  
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